Results 111 to 120 of about 8,866 (177)

Bruton's Tyrosine Kinase Inhibitor Zanubrutinib Effectively Modulates Cancer Resistance by Inhibiting Anthracycline Metabolism and Efflux. [PDF]

Pharmaceutics, 2022
Čermáková L, Hofman J, Laštovičková L, Havlíčková L, Špringrová I, Novotná E, Wsól V.   +6 more
europepmc   +1 more source

Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma. [PDF]

J Immunother Cancer, 2023
Sinha M, Betts C, Zhang L, Griffith MJ, Solman I, Chen B, Liu E, Tamaki W, Stultz J, Marquez J, Sivagnanam S, Cheung A, Pener D, Fahlman A, Taber E, Lerner K, Crocker M, Todd K, Rajagopalan B, Ware C, Bridge M, Vo J, Dragomanovich H, Sudduth-Klinger J, Vaccaro G, Lopez CD, Tempero M, Coussens LM, Fong L.   +28 more
europepmc   +1 more source

TP53-altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor-based therapy: A retrospective analysis. [PDF]

Am J Hematol, 2022
Cherng HJ, Khwaja R, Kanagal-Shamanna R, Tang G, Burger J, Thompson P, Ferrajoli A, Estrov Z, Sasaki K, Sampath D, Wang X, Kantarjian H, Keating M, Wierda WG, Jain N.   +14 more
europepmc   +1 more source

Durable remission with Bruton's tyrosine kinase inhibitor therapy in a patient with leptomeningeal disease secondary to relapsed mantle cell lymphoma. [PDF]

BMJ Case Rep, 2022
Yohannan B, Sridhar A, Nguyen N, Rios A.
europepmc   +1 more source

Irreversible covalent Bruton's tyrosine kinase inhibitor, TAS5315 versus placebo in rheumatoid arthritis patients with inadequate response to methotrexate: a randomised, double-blind, phase IIa trial. [PDF]

Ann Rheum Dis, 2023
Takeuchi T, Tanaka S, Murata M, Tanaka Y.   +3 more
europepmc   +1 more source

Evobrutinib, a covalent Bruton's tyrosine kinase inhibitor: Mass balance, elimination route, and metabolism in healthy participants. [PDF]

Clin Transl Sci, 2021
Scheible H, Dyroff M, Seithel-Keuth A, Harrison-Moench E, Mammasse N, Port A, Bachmann A, Dong J, van Lier JJ, Tracewell W, Mitchell D.   +10 more
europepmc   +1 more source

Development of a novel Bruton's tyrosine kinase inhibitor that exerts anti-cancer activities potentiates response of chemotherapeutic agents in multiple myeloma stem cell-like cells. [PDF]

Front Pharmacol, 2022
Elbezanti WO, Al-Odat OS, Chitren R, Singh JK, Srivastava SK, Gowda K, Amin S, Robertson GP, Nemmara VV, Jonnalagadda SC, Budak-Alpdogan T, Pandey MK.   +11 more
europepmc   +1 more source

Prevention of Bone Destruction by Mechanical Loading Is Not Enhanced by the Bruton's Tyrosine Kinase Inhibitor CC-292 in Myeloma Bone Disease. [PDF]

Int J Mol Sci, 2021
Ziouti F, Rummler M, Steyn B, Thiele T, Seliger A, Duda GN, Bogen B, Willie BM, Jundt F.   +8 more
europepmc   +1 more source

Bortezomib enhances the anti-cancer effect of the novel Bruton's tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK. [PDF]

Aging (Albany NY), 2021
Wang X, Fei Y, Liu X, Zhang T, Li W, Jia X, Liu X, Qiu L, Qian Z, Zhou S, Ren X, Zhai Q, Meng B, Li L, Zhang H.   +14 more
europepmc   +1 more source

Cryptococcal Infection in a Patient With Chronic Lymphocytic Leukaemia Receiving Acalabrutinib, a Bruton's Tyrosine Kinase Inhibitor: A Case Report. [PDF]

Cureus
Al-Shaker AN, Agarwal A, Saeed MT, Marney Z.   +3 more
europepmc   +1 more source